Seed/Nut/Grain Variants · Other
Quinoa Bran (Chenopodium quinoa) (Chenopodium quinoa)
Preliminary EvidenceCompound
Hermetica Superfood Encyclopedia
Quinoa bran, derived from the outer layer of Chenopodium quinoa seeds, is rich in saponins, flavonoids (quercetin, kaempferol), and dietary fiber that drive its hepatoprotective and antioxidant effects. Its primary bioactive compounds modulate lipid metabolism and oxidative stress pathways, making it a subject of growing preclinical research for liver and kidney health.
Quinoa bran is the outer layer of the seed from Chenopodium quinoa Willd., a pseudocereal plant native to the Andean regions of South America, particularly Peru. It is obtained as a byproduct during quinoa seed milling or processing through mechanical separation, with extracts typically prepared using solvents like ethanol, water, or deep eutectic solvents.
No human clinical trials, RCTs, or meta-analyses on quinoa bran were identified. All evidence comes from preclinical animal studies including research on metabolic dysfunction-associated steatotic liver disease in mice (PMID: 41508502), hyperuricemia models (PMID: 37083411), and CCl4-induced liver fibrosis prevention in BALB/c mice.
No clinically studied human dosages exist. Animal studies used quinoa bran terpenoids for liver conditions (dose unspecified), QBS4 saponins for hyperuricemia (dose unspecified), and red quinoa bran extracts at 1.54 g/kg containing rutin at 3.92 mg/kg/day in mice. Consult a healthcare provider before starting any new supplement.
Quinoa bran is the outer layer removed during quinoa processing and is notably nutrient-dense. Protein content ranges approximately 15–20% by dry weight, containing all essential amino acids with lysine (~5–6 g/100g protein) being particularly notable compared to cereal grains. Dietary fiber is high at approximately 8–15% dry weight, comprising both insoluble fiber (cellulose, hemicellulose) and soluble fractions. Fat content is approximately 6–10% dry weight, rich in polyunsaturated fatty acids including linoleic acid (omega-6, ~50–55% of total fatty acids) and alpha-linolenic acid (omega-3, ~5–8% of total fatty acids). Key bioactive compounds include saponins (2–5% dry weight in unprocessed bran; triterpenoid glycosides such as oleanolic acid, hederagenin, and phytolacchagenic acid derivatives), which are responsible for bitter taste and are partly removed during processing. Polyphenols are present at approximately 200–500 mg GAE/100g dry weight, including ferulic acid, kaempferol, quercetin, and rutin. Betalains (betacyanins and betaxanthins) are present in colored varieties. Tocopherols (vitamin E) are found at approximately 5–10 mg/100g, primarily as alpha- and gamma-tocopherol. Minerals include magnesium (~250–300 mg/100g), phosphorus (~400–500 mg/100g), potassium (~600–700 mg/100g), iron (~8–10 mg/100g, though bioavailability is reduced by phytates estimated at 1–2% dry weight), zinc (~3–4 mg/100g), and manganese (~2–3 mg/100g). B vitamins are present including folate (~150–200 µg/100g), riboflavin (B2, ~0.3–0.4 mg/100g), and niacin (~1–2 mg/100g). Phytosterols (beta-sitosterol, campesterol) are present at approximately 50–100 mg/100g. Starch content is lower than whole quinoa at approximately 10–20% dry weight with a portion being resistant starch. Bioavailability note: antinutrients including phytates, oxalates, and saponins in unprocessed bran reduce mineral absorption and protein digestibility; processing methods such as washing, soaking, or heat treatment can reduce saponins by 60–80% and improve overall bioavailability. Data is primarily derived from South American commercial quinoa varieties (white, red, black) and may vary by cultivar and processing method.
Quinoa bran's saponins and polyphenols — particularly quercetin and kaempferol — suppress NF-κB signaling to reduce pro-inflammatory cytokine expression (TNF-α, IL-6) in hepatic tissue. Its fiber and saponin content inhibits intestinal cholesterol and lipid absorption, reducing hepatic lipid deposition linked to non-alcoholic fatty liver progression. Additionally, its antioxidant compounds upregulate Nrf2/HO-1 pathway activity, enhancing endogenous antioxidant defenses and reducing TGF-β1-mediated fibrotic signaling in liver stellate cells.
Current evidence for quinoa bran is limited to preclinical animal studies, with no completed randomized controlled trials in humans as of early 2025. Rodent models of hyperuricemia have shown reductions in serum uric acid levels and improvements in kidney function markers (creatinine, blood urea nitrogen) following quinoa bran administration, though doses and durations vary across studies. Hepatoprotective effects, including reduced ALT/AST levels and decreased hepatic triglyceride accumulation, have been observed in diet-induced fatty liver animal models. The evidence base is promising but insufficient to establish clinical efficacy, effective dosages, or long-term safety in humans.
No formal human safety trials for isolated quinoa bran extract exist, though whole quinoa is generally recognized as safe and well-tolerated. The saponin content, if insufficiently processed, may cause gastrointestinal irritation including bloating, nausea, or loose stools, particularly at high supplemental doses. Individuals taking uric acid-lowering drugs (e.g., allopurinol, febuxostat) or lipid-lowering medications (statins, fibrates) should exercise caution due to potential additive effects. Pregnant or breastfeeding women should avoid supplemental quinoa bran extracts until human safety data are available, though dietary consumption of quinoa is considered safe.
